Abdomen: normal variations and benign conditions resulting in uptake on FDG-PET/CT

Katherine Zukotynski; Chun K Kim

doi:10.1016/j.cpet.2013.10.008

Abdomen: normal variations and benign conditions resulting in uptake on FDG-PET/CT

PET Clin. 2014 Apr;9(2):169-83. doi: 10.1016/j.cpet.2013.10.008. Epub 2014 Jan 3.

Authors

Katherine Zukotynski¹, Chun K Kim²

Affiliations

¹ Department of Medical Imaging, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, University of Toronto, Toronto, Ontario M4N 3M5, Canada; Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
² Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. Electronic address: ckkim@bwh.harvard.edu.

PMID: 25030280
DOI: 10.1016/j.cpet.2013.10.008

Abstract

The increasing use of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in oncology has led to: improved sensitivity and specificity in detecting localized and metastatic disease, increased ability to target biopsies to the site of most aggressive disease, and development of a noninvasive biomarker to assess prognosis and effects of therapy. However, for correct interpretation of FDG-PET/CT studies, an understanding of both normal and abnormal imaging appearances commonly encountered in oncology patients is important. This article discusses commonly seen normal variations and benign findings on FDG-PET/CT of the abdomen.

Keywords: (18)F-Fluorodeoxyglucose PET/computed tomography; Abdomen; Benign findings; Imaging; Normal variations.

Publication types

Review

MeSH terms

Abdomen / diagnostic imaging*
Abdominal Fat / diagnostic imaging
Abdominal Fat / metabolism
Abdominal Muscles / diagnostic imaging
Abdominal Muscles / metabolism
Artifacts
Digestive System Diseases / diagnostic imaging
Digestive System Diseases / metabolism
Fluorodeoxyglucose F18* / pharmacokinetics
Humans
Multimodal Imaging / methods*
Positron-Emission Tomography / methods*
Radiopharmaceuticals* / pharmacokinetics
Tissue Distribution
Tomography, X-Ray Computed / methods*
Urologic Diseases / diagnostic imaging
Urologic Diseases / metabolism

Substances

Radiopharmaceuticals
Fluorodeoxyglucose F18